Gravesí Disease - Market Insights, Epidemiology and Market Forecast-2028

Gravesí Disease - Market Insights, Epidemiology and Market Forecast-2028

  • Pages: 148
  • Geography: Global
  • Delivery Timeline: 24 hours
  • Publication: Jan, 2019
  • SKU: DIMI0291
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Graves’ Disease - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Graves’ Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Graves’ Disease (GD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered

  •  The United States
  •  EU5 (Germany, France, Italy, Spain and the United Kingdom)
  •  Japan

Study Period: 2017-2028
Graves’ Disease - Disease Understanding
Graves' disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body—even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves’ disease also can affect the eyes and skin.
Graves' disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body—even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves’ disease also can affect the eyes and skin.
The DelveInsight Graves’ Disease (GD) market report gives a thorough understanding of the Graves’ Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Graves’ Disease in the US, Europe, and Japan.
Graves’ Disease Epidemiology
The Graves’ Disease (GD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total incident population, diagnosed incident population, age-specific incident population, gender-specific incident population and by Clinical Manifestations of Graves’ disease.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Graves’ Disease was estimated to be 384,538 [7MM] in 2018. United States accounts for the highest Graves’ Disease cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Graves’ Disease, followed by France with an incident population of 33,365 in 2018.
Graves’ Disease Management
This segment of the Graves’ Disease report encloses the key-cross analysis of marketed drugs.
Currently, there is no cure for Graves’ disease. The goals of treatment of Graves' disease are to control symptoms efficiently and restore euthyroidism. The three options for treating patients with hyperthyroidism are anti-thyroid drugs (Tapazole (Methimazole), Carbimazole and Propylthiouracil) radioactive iodine ablation, and surgery. All three therapeutic options would be effective in the treatment of patients with Graves’ disease, whereas patients with toxic adenoma or toxic multinodular goiter should have either radioactive iodine therapy or surgery since these patients rarely go into remission. In patients with toxic nodular goiter, ATDs are generally used to restore euthyroidism before definitive treatment with surgery or radioactive iodine and infrequently used as a long-term treatment when the other two therapies are contraindicated, or the patient has a short life expectancy. If drugs were used as the primary therapy, it should be given for at least 12-18 months. In case of surgery is chosen for primary therapy, near total or total thyroidectomy is the choice of surgery. RAI therapy can be done if there are side effects of the anti-thyroid drugs, history of neck surgery or external neck radiation. Beta-blocker can be used to reduce signs and symptoms of thyrotoxicosis and to inhibit the conversion of T4 to T3 in the peripheral organs.
Graves’ Disease Market Outlook
The Graves’ Disease (GD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Antithyroid drugs are the most recommended treatment of Graves’ Disease. Methimazole is the utmost prescribed antithyroid drug in the US, Japan, Germany, France, Italy and Spain, however, Carbimazole is preferred by the UK doctors. Radioactive Iodine method has gained its importance in last few years with low dose requirement and comparatively low relapse rate. Thyroid surgery is mostly recommended in complicated cases were RAI and antithyroid drugs are not a choice.
According to DelveInsight, the global market of Graves’ Disease (GD) was estimated to be USD 306.3 million in 2018. The United States accounts for the largest market size of Graves’ Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size with 27.1 million in 2018, while Spain had the lowest market size of Graves’ Disease (GD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Graves’ Disease Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The entry of novel drug CFZ533, Novartis by 2024 may drive the otherwise stringent therapeutic market of the Grave’s Disease.
 
Graves’ Disease Report Insights

  •  Patient Population
  •  Therapeutic Approaches
  • Pipeline Analysis
  •  Market Size and Trends
  •  Market Opportunities
  •  Impact of upcoming Therapies

Graves’ Disease Report Key Strengths

  •  10 Year Forecast
  •  7MM Coverage
  •  Epidemiology Segmentation
  • Drugs Uptake
  •  Highly Analyzed Market
  •  Key Cross Competition

Graves’ Disease Report Assessment

  •  Current Treatment Practices
  •  Unmet Needs
  •  Detailed Pipeline Product Profiles
  •  Market Attractiveness
  •  Market Drivers and Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Graves’ Disease market.
  •  Organize sales and marketing efforts by identifying the best opportunities for Graves’ Disease market.
  •  To understand the future market competition in the Graves’ Disease market.

1 Key Insights
2 Graves’ disease Market Overview at a Glance
2.1 Market Share (%) Distribution of Graves’ disease in 2017
2.2 Market Share (%) Distribution of Graves’ disease in 2028
3 Disease Overview: Graves’ Disease
3.1 Introduction
3.2 Causes and Symptoms of Graves’ disease
3.3 Clinical Manifestations of Graves’ disease
3.4 Pathophysiology of Graves’ disease
3.5 Pathophysiology of Graves’ Ophthalmopathy
3.6 Genetic Basis of Graves’ Disease
3.7 Diagnosis
3.7.1 Diagnostic Criteria for Thyroid Storm (TS) of the Japan Thyroid Association
3.7.2 The Burch-Wartofsky Point Scale for Diagnosis of Thyroid Storm
3.7.3 Diagnosis and Differential Diagnosis of Thyroid Dermopathy
3.7.4 Japan Thyroid Association: Guidelines for the Diagnosis of Graves ‘disease
3.8 Sensitive Biomarkers of Graves’ disease
3.9 Risk Factors and Complications
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 7MM Total Incident Patient Population of GD
5 Country Wise-Epidemiology of GD
5.1 United States
5.1.1 Assumptions and Rationale
5.1.2 Total Incident cases of Graves’ disease in the US
5.1.3 Gender Specific Incident cases of Graves’ disease in the US
5.1.4 Age Specific Incident cases of Graves’ disease in the US
5.1.5 Diagnosed Incident Cases of Graves’ disease in the US
5.1.6 Clinical Manifestations of Graves’ disease in the US
5.2 EU5
5.2.1 Assumptions and Rationale
5.2.2 Germany
5.2.2.1 Total Incident cases of Graves’ disease in Germany
5.2.2.2 Gender Specific Incident cases of Graves’ disease in Germany
5.2.2.3 Age Specific Incident cases of Graves’ disease in Germany
5.2.2.4 Diagnosed Incident Cases of Graves’ disease in Germany
5.2.2.5 Clinical Manifestations of Graves’ disease in Germany
5.2.3 France
5.2.3.1 Total Incident cases of Graves’ disease in France
5.2.3.2 Gender Specific Incident cases of Graves’ disease in France
5.2.3.3 Age Specific Incident cases of Graves’ disease in France
5.2.3.4 Diagnosed Incident Cases of Graves’ disease in France
5.2.3.5 Clinical Manifestations of Graves’ disease in France
5.2.4 Italy
5.2.4.1 Total Incident cases of Graves’ disease in Italy
5.2.4.2 Gender Specific Incident cases of Graves’ disease in Italy
5.2.4.3 Age Specific Incident cases of Graves’ disease in Italy
5.2.4.4 Diagnosed Incident Cases of Graves’ disease in Italy
5.2.4.5 Clinical Manifestations of Graves’ disease in Italy
5.2.5 Spain
5.2.5.1 Total Incident cases of Graves’ disease in Spain
5.2.5.2 Gender Specific Incident cases of Graves’ disease in Spain
5.2.5.3 Age Specific Incident cases of Graves’ disease in Spain
5.2.5.4 Diagnosed Incident Cases of Graves’ disease in Spain
5.2.5.5 Clinical Manifestations of Graves’ disease in Spain
5.2.6 United Kingdom
5.2.6.1 Total Incident cases of Graves’ disease in the UK
5.2.6.2 Gender Specific Incident cases of Graves’ disease in the UK
5.2.6.3 Age-Specific Incident cases of Graves’ disease in the UK
5.2.6.4 Diagnosed Incident Cases of Graves’ disease in the UK
5.2.6.5 Clinical Manifestations of Graves’ disease in the UK
5.3 Japan
5.3.1 Assumptions and Rationale
5.3.2 Total Incident cases of Graves’ disease in Japan
5.3.3 Gender Specific Incident cases of Graves’ disease in Japan
5.3.4 Age Specific Incident cases of Graves’ disease in Japan
5.3.5 Diagnosed Incident Cases of Graves’ disease in Japan
5.3.6 Clinical Manifestations of Graves’ disease in Japan
6 Current Treatment Practices
7 Practice Guidelines for Graves’ disease
7.1 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
7.2 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
7.3 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy
7.4 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society
8 Unmet Needs
9 Marketed Drugs
9.1 Key Cross of Marketed Drugs
10 Emerging Therapies
10.1 Key Cross of Emerging Therapies
10.2 CFZ 533: Novartis
10.2.1 Product Description
10.2.2 Clinical Development
10.2.2.1 Clinical Trials Information
10.2.3 Advantages and Disadvantages
10.2.4 Safety and Efficacy
10.2.5 Product Profile
11 Graves’ disease: 7 Major Market Analysis
11.1 Key Findings
11.2 Market Size of GD in 7MM
12 Market Outlook by Country
13 The United States: Market Outlook
13.1 United States Market Size
13.1.1 Total Market size of GD
13.1.2 GD Market by Therapies
14 EU-5 Countries: Market Outlook
14.1 Germany Market Size
14.1.1 Total Market size of GD
14.1.2 GD Market by Therapies
14.2 France Market Size
14.2.1 Total Market size of GD
14.2.2 GD Market by Therapies
14.3 Italy Market Size
14.3.1 Total Market size of GD
14.3.2 GD Market by Therapies
14.4 United Kingdom Market Size
14.4.1 Total Market size of GD
14.4.2 GD Market by Therapies
14.5 Spain Market Size
14.5.1 Total Market size of GD
14.5.2 GD Market by Therapies
15 Japan: Market Outlook
15.1 Japan Market Size
15.1.1 Total Market size of GD
15.1.2 GD Market by Therapies
16 Market Drivers
17 Market Barriers
18 Appendix
18.1 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Table 14: Clinical manifestations of Graves’ disease in Germany (2016-2028)
Table 15: Total Incident Cases of GD in France (2016-2028)
Table 16: Gender Specific Incident Cases of GD in France (2016-2028)
Table 17: Age-Specific Incident Cases of GD in France (2016-2028)
Table 18: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Table 19: Clinical manifestations of Graves’ disease in France (2016-2028)
Table 20: Total Incident Cases of GD in Italy (2016-2028)
Table 21: Gender Specific Incident Cases of GD in Italy (2016-2028)
Table 22: Age-Specific Incident Cases of GD in Italy (2016-2028)
Table 23: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Table 24: Clinical manifestations of Graves’ disease in Italy (2016-2028)
Table 25: Total Incident Cases of GD in Spain (2016-2028)
Table 26: Gender Specific Incident Cases of GD in Spain (2016-2028)
Table 27: Age-Specific Incident Cases of GD in Spain (2016-2028)
Table 28: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Table 29: Clinical manifestations of Graves’ disease in Spain (2016-2028)
Table 30: Total Incident Cases of GD in the UK (2016-2028)
Table 31: Gender Specific Incident Cases of GD in the UK (2016-2028)
Table 32: Age-Specific Incident Cases of GD in the UK (2016-2028)
Table 33: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Table 34: Clinical manifestations of Graves’ disease in the UK (2016-2028)
Table 35: Total Incident Cases of GD in Japan (2016-2028)
Table 36: Gender Specific Incident Cases of GD in Japan (2016-2028)
Table 37: Age-Specific Incident Cases of GD in Japan (2016-2028)
Table 38: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Table 39: Clinical manifestations of Graves’ disease in Japan (2016-2028)
Table 40: Key Cross of Marketed Drugs
Table 41: Key Cross of Emerging Therapies
Table 42: CFZ533, Clinical Trial Description, 2018
Table 43: 7 Major Market Size of GD in USD Million (2016-2028)
Table 44: United States Market Size of GD in USD Million (2016-2028)
Table 45: United States Market Size of GD by Therapies in USD Million (2016-2028)
Table 46: Germany Market Size of GD in USD Million (2016-2028)
Table 47: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Table 48: France Market Size of GD in USD Million (2016-2028)
Table 49: France Market Size of GD by Therapies in USD Million (2016-2028)
Table 50: Italy Market Size of GD in USD Million (2016-2028)
Table 51: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Table 52: United Kingdom Market Size of GD in USD Million (2016-2028)
Table 53: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Table 54: Spain Market Size of GD in USD Million (2016-2028)
Table 55: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Table 56: Japan Market Size of GD in USD Million (2016-2028)
Table 57: Japan Market Size of GD by Therapies in USD Million (2016-2028)

Figure 1: Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy
Figure 2: Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
Figure 3: Theoretical Model of Intrathyroidal Graves’ Disease
Figure 4: An approach to the Diagnosis of Graves’ disease
Figure 5: Incident Patient Population of GD in the 7MM (2016-2028)
Figure 6: Total Incident Cases of GD in the US (2016-2028)
Figure 7: Gender Specific Incident Cases of GD in the US (2016-2028)
Figure 8: Age-Specific Incident Cases of GD in the US (2016-2028)
Figure 9: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Figure 10: Clinical Manifestations of Graves’ disease in the US (2016-2028)
Figure 11: Total Incident Cases of GD in Germany (2016-2028)
Figure 12: Gender Specific Incident Cases of GD in Germany (2016-2028)
Figure 13: Age-Specific Incident Cases of GD in Germany (2016-2028)
Figure 14: Diagnosed Incident Cases of Graves’ disease in Germany (2016-2028)
Figure 15: Clinical Manifestations of Graves’ disease in Germany (2016-2028)
Figure 16: Total Incident Cases of GD in France (2016-2028)
Figure 17: Gender Specific Incident Cases of GD in France (2016-2028)
Figure 18: Age-Specific Incident Cases of GD in France (2016-2028)
Figure 19: Diagnosed Incident Cases of Graves’ disease in France (2016-2028)
Figure 20: Clinical Manifestations of Graves’ disease in France (2016-2028)
Figure 21: Total Incident Cases of GD in Italy (2016-2028)
Figure 22: Gender Specific Incident Cases of GD in Italy (2016-2028)
Figure 23: Age-Specific Incident Cases of GD in Italy (2016-2028)
Figure 24: Diagnosed Incident Cases of Graves’ disease in Italy (2016-2028)
Figure 25: Clinical Manifestations of Graves’ disease in Italy (2016-2028)
Figure 26: Total Incident Cases of GD in Spain (2016-2028)
Figure 27: Gender Specific Incident Cases of GD in Spain (2016-2028)
Figure 28: Age-Specific Incident Cases of GD in Spain (2016-2028)
Figure 29: Diagnosed Incident Cases of Graves’ disease in Spain (2016-2028)
Figure 30: Clinical Manifestations of Graves’ disease in Spain (2016-2028)
Figure 31: Total Incident Cases of GD in the UK (2016-2028)
Figure 32: Gender Specific Incident Cases of GD in the UK (2016-2028)
Figure 33: Age-Specific Incident Cases of GD in the UK (2016-2028)
Figure 34: Diagnosed Incident Cases of Graves’ disease in the UK (2016-2028)
Figure 35: Clinical Manifestations of Graves’ disease in the UK (2016-2028)
Figure 36: Total Incident Cases of GD in Japan (2016-2028)
Figure 37: Gender Specific Incident Cases of GD in Japan (2016-2028)
Figure 38: Age-Specific Incident Cases of GD in Japan (2016-2028)
Figure 39: Diagnosed Incident Cases of Graves’ disease in Japan (2016-2028)
Figure 40: Clinical Manifestations of Graves’ disease in Japan (2016-2028)
Figure 41: Management of Hyperthyroidism
Figure 42: Algorithm for the management of a patient with Graves’ hyperthyroidism
Figure 43: Unmet Needs for Graves’ disease
Figure 44: 7 Major Market Size of GD in USD Million (2016-2028)
Figure 45: United States Market Size of GD in USD Million (2016-2028)
Figure 46: United States Market Size of GD by Therapies in USD Million (2016-2028)
Figure 47: Germany Market Size of GD in USD Million (2016-2028)
Figure 48: Germany Market Size of GD by Therapies in USD Million (2016-2028)
Figure 49: France Market Size of GD in USD Million (2016-2028)
Figure 50: France Market Size of GD by Therapies in USD Million (2016-2028)
Figure 51: Italy Market Size of GD in USD Million (2016-2028)
Figure 52: Italy Market Size of GD by Therapies in USD Million (2016-2028)
Figure 53: United Kingdom Market Size of GD in USD Million (2016-2028)
Figure 54: United Kingdom Market Size of GD by Therapies in USD Million (2016-2028)
Figure 55: Spain Market Size of GD in USD Million (2016-2028)
Figure 56: Spain Market Size of GD by Therapies in USD Million (2016-2028)
Figure 57: Japan Market Size of GD in USD Million (2016-2028)
Figure 58: Japan Market Size of GD by Therapies in USD Million (2016-2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Table 1: Diagnostic Criteria For Thyroid Storm (TS) of the Japan Thyroid Association
Table 2: Diagnostic Criteria For Thyroid Storm (TS) based on Grades
Table 3: The Burch - Wartofsky Point Scale for Diagnosis of Thyroid Storm
Table 4: Incident Patient Population of GD in the 7MM (2016-2028)
Table 5: Total Incident Cases of GD in the US (2016-2028)
Table 6: Gender Specific Incident Cases of GD in the US (2016-2028)
Table 7: Age-Specific Incident Cases of GD in the US (2016-2028)
Table 8: Diagnosed Incident Cases of Graves’ disease in the US (2016-2028)
Table 9: Clinical manifestations of Graves’ disease in the US (2016-2028)
Table 10: Total Incident Cases of GD in Germany (2016-2028)
Table 11: Gender Specific Incident Cases of GD in Germany (2016-2028)
Table 12: Age-Specific Incident Cases of GD in Germany (2016-2028)
Table 13: Diagnosed Incident Case